Pfizer and BioNTech's COVID-19 Vaccine Booster Receive the US FDA's EUA for the Treatment of COVID-19
Shots:
- The US FDA has issued a EUA for the COVID-19 booster vaccine (administered at least 6mos. after completion of primary 2 doses) to prevent COVID-19 in individuals aged ≥65yrs. & 18 through 64yrs. of age who at high risk of severe COVID-19
- The EUA is based on clinical data that showed higher neutralizing Ab titers against COVID-19 & other variants compared with the levels observed after 2 doses- frequency of reactions was similar or lower than after dose two & AEs was consistent with other clinical safety data
- Previously- a third dose of the vaccine was authorized for individuals aged 12yrs. who have undergone a solid organ transplant or diagnosed with other conditions
Ref: Pfizer | Image: Wall Street Journal
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com